{"product_id":"biontech-business-model-canvas","title":"BioNTech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech Business Model Canvas: Strategic Blueprint for Investors \u0026amp; Strategists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind BioNTech's business model with our detailed Business Model Canvas—revealing value propositions, key partners, revenue streams, and growth levers to inform investment or strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech's long-term alliance with Pfizer covers global distribution and joint mRNA R\u0026amp;D, generating 2021–2023 vaccine revenues where Pfizer\/BioNTech reported roughly $54B total COVID-19 vaccine sales through 2023 and ongoing milestone payments; Pfizer's regulatory and commercial scale accelerates launches and reimbursement access worldwide.\u003c\/p\u003e\n\u003cp\u003eRegional partnerships like Fosun Pharma grant localized manufacturing and China regulatory access—Fosun paid $75M upfront in 2020 and led Greater China distribution, ensuring compliance and market penetration in a \u0026gt;1.4B population market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech partners with over 120 academic and research institutions, including Mainz University and the Karolinska Institutet, accelerating early-stage discovery and access to top immunology talent; joint projects contributed to 35 peer-reviewed papers in 2024 that validated its mRNA and CAR-T platforms. These collaborations supplied novel targets for programs that helped BioNTech report €1.8bn R\u0026amp;D investment in 2024, strengthening global scientific validation and pipeline depth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental and Health Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with CEPI (Coalition for Epidemic Preparedness Innovations) and national health ministries supply non-dilutive funding—CEPI committed over $3.5B globally by 2025—and underpinned BioNTech’s pandemic programs, offsetting costs for vaccines and infectious-disease R\u0026amp;D that lack commercial pull. These partners also help accelerate regulatory reviews and secure emergency use or orphan-drug pathways, cutting time-to-market by months during crises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioNTech relies on specialized CDMOs to scale mRNA oncology drugs, securing capacity and expertise for temperature-sensitive lipid nanoparticles and high-purity mRNA; by end-2025 the company targets \u0026gt;1.5 million dose-equivalents annual capacity via partners including Catalent and Rentschler, supporting resilient global supply chains.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCDMO capacity target: \u0026gt;1.5M dose-equivalents (2025)\u003c\/li\u003e\n\u003cli\u003eKey partners: Catalent, Rentschler (commercial scale)\u003c\/li\u003e\n\u003cli\u003eCritical tech: lipid nanoparticle cold chain, aseptic mRNA purity\u003c\/li\u003e\n\u003cli\u003eRole: scale, regulatory batch release, geographic redundancy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Co-development Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioNTech co-develops individualized neoantigen immunotherapies with partners like Genentech (Roche) to share steep costs and technical risk; their 2024 alliance investments exceeded $500m and target faster Phase II\/III enrollment using partner trial infrastructure.\u003c\/p\u003e\n\u003cp\u003eThese deals pair BioNTech’s mRNA platform with partners’ oncology trial management and commercial reach, aiming to cut time-to-market by 12–18 months versus solo programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner: Genentech (Roche)\u003c\/li\u003e\n\u003cli\u003e2024 alliance funding: \u0026gt;$500m\u003c\/li\u003e\n\u003cli\u003eRisk: shared R\u0026amp;D and manufacturing costs\u003c\/li\u003e\n\u003cli\u003eBenefit: trial ops + commercial scale\u003c\/li\u003e\n\u003cli\u003eExpected faster launch: 12–18 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech’s partners fast‑track global scale: funding, China access, 12–18m time‑to‑market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech’s key partnerships (Pfizer, Fosun, Catalent, Rentschler, Genentech, CEPI, 120+ academia) provide global distribution, China access, CDMO capacity (\u0026gt;1.5M dose-eq target 2025), shared R\u0026amp;D funding (\u0026gt;€1.8bn R\u0026amp;D 2024; \u0026gt;$500m Genentech 2024), and non-dilutive grants (CEPI ~$3.5B by 2025) to accelerate trials, scale manufacturing, and reduce time-to-market by 12–18 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eGlobal commercial+R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$54B vaccine sales (2021–23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFosun\u003c\/td\u003e\n\u003ctd\u003eChina access\u003c\/td\u003e\n\u003ctd\u003e$75M upfront (2020)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.5M dose-eq (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenentech\u003c\/td\u003e\n\u003ctd\u003eCo‑dev oncology\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEPI\u003c\/td\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003e~$3.5B (by 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for BioNTech outlining its nine blocks—customer segments (governments, healthcare providers, biopharma partners, patients), value propositions (mRNA therapeutics\/vaccines, personalized oncology), channels (clinical, partner networks, direct sales), revenue streams (product sales, collaborations, licensing), key resources\/activities\/partners, cost structure, and SWOT-aligned competitive advantages for investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of BioNTech’s business model as a pain-point reliever, condensing their R\u0026amp;D-driven platform, partnerships, and regulatory pathways into an editable one-page snapshot for rapid strategic alignment and stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech’s R\u0026amp;D focuses on mRNA, cell therapies, and antibody-drug conjugates, funding ~€1.2bn R\u0026amp;D spend in 2024 to discover antigens and improve delivery (lipid nanoparticles, vectors) and keep a ~60-program clinical pipeline as of Dec 2024; this continuous cycle secures IP, drives filings, and aims to shorten time-to-first-in-human while supporting revenue diversification beyond COVID-19 vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioNTech runs 100+ clinical trials (Phases 1–3) across oncology and infectious diseases, handling patient recruitment, central data monitoring, and GCP\/regulatory compliance across EU, US, and China; 2024 R\u0026amp;D spend was €2.7bn, tied to trial activities. Successful trial readouts (e.g., 2023\/24 mRNA oncology signals raising market cap moves of \u0026gt;€10bn) directly determine valuation and commercial rollout timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech runs sophisticated manufacturing sites and modular BioNTainers for rapid, local deployment; as of 2024 it reported capacity to produce hundreds of millions of mRNA doses annually, with BioNTainers cutting setup time to weeks. \u003c\/p\u003e\n\u003cp\u003eOperations center on high-precision mRNA synthesis and lipid nanoparticle (LNP) formulation, with continuous, resource-intensive GMP compliance—capital and R\u0026amp;D spending totaled €1.9bn in 2024 to support scale-up and regulatory approval. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating global healthcare regulations is continuous: BioNTech filed 2024 supplemental dossiers to FDA and EMA for mRNA-based oncology and respiratory programs and maintained EU conditional marketing authorizations for Comirnaty with 2024 pharmacovigilance reports covering \u0026gt;2.1M safety reports worldwide.\u003c\/p\u003e\n\u003cp\u003eBioNTech runs ongoing post-market surveillance, safety reporting, and periodic benefit–risk updates to retain authorizations and support label expansions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiles: FDA, EMA, national agencies\u003c\/li\u003e\n\u003cli\u003e2024 safety reports: \u0026gt;2.1M cases\u003c\/li\u003e\n\u003cli\u003eKey tasks: dossiers, PV (pharmacovigilance), periodic benefit–risk\u003c\/li\u003e\n\u003cli\u003eObjective: maintain authorizations, enable label expansions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBioNTech protects long-term revenue by running a broad patent program covering mRNA stabilization, lipid nanoparticle delivery, and target-specific sequences; its portfolio exceeds 3,000 granted and pending patents as of 2025. The company actively files new claims and spent roughly €120–150m annually on IP and legal defenses in 2024–2025 to deter infringements and preserve licensing income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePortfolio: \u0026gt;3,000 patents (2025)\u003c\/li\u003e\n\u003cli\u003eFocus: mRNA stabilization, delivery systems, therapeutic targets\u003c\/li\u003e\n\u003cli\u003eActions: filing new patents, litigation\/defense\u003c\/li\u003e\n\u003cli\u003eIP spend: ~€120–150m\/year (2024–2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech: €2.7bn R\u0026amp;D, 60 programs, 100+ trials, 3,000+ patents, rapid modular deployment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioNTech runs R\u0026amp;D (mRNA, cell therapy, ADCs) with ~€2.7bn R\u0026amp;D spend in 2024, ~60 clinical programs, 100+ trials, GMP manufacturing capacity for hundreds of millions mRNA doses, \u0026gt;3,000 patents (2025) and ~€120–150m IP spend; regulatory filings, PV (\u0026gt;2.1M safety reports in 2024) and BioNTainer modular sites shorten deployment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e€2.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e~60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP spend\u003c\/td\u003e\n\u003ctd\u003e€120–150m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety reports 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact BioNTech Business Model Canvas you’ll receive—no mockup or sample—showing real sections from the final file.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your purchase, you’ll get this same professionally formatted document in full, ready to edit, present, and share.\u003c\/p\u003e\n\u003cp\u003eNo surprises or fillers: the preview matches the deliverable and includes all content and pages upon download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749780697465,"sku":"biontech-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biontech-business-model-canvas.png?v=1772218388","url":"https:\/\/matrixbcg.com\/products\/biontech-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}